Arcus Biosciences Inc. (RCUS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Arcus Biosciences Inc. (RCUS:NYSE), powered by AI.

Current Price
$26.45
P/E Ratio
-8.0
Market Cap
2.8B
Sector
Healthcare
What is the Arcus Biosciences Inc. stock price forecast?

Arcus Biosciences Inc. is currently trading at $26.45. View real-time AI analysis on Alpha Lenz.

What is Arcus Biosciences Inc. insider trading activity?

View the latest insider trading data for Arcus Biosciences Inc. on Alpha Lenz.

What is Arcus Biosciences Inc.'s P/E ratio?

Arcus Biosciences Inc.'s P/E ratio is -8.0.

Arcus Biosciences Inc.

NYSE · RCUS
$26.45-0.60(-2.22%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Arcus Biosciences Inc.'s future dividend policy...
Alpha Chat Insight

Arcus Biosciences Inc. trades at a P/E of -8.0 (undervalued) with modest ROE of -63.3%. 3Y revenue CAGR of 30.2% highlights clear growth momentum.

Ask for details

Company Overview

Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small molecules, and combination therapies that address different aspects of cancer's complex biology. One of its core strategies is to develop next-generation treatments that can potentially improve upon existing therapies, enhancing efficacy while minimizing side effects. Operating in an industry marked by rapid scientific advancements, Arcus Biosciences plays a critical role in the ongoing pursuit of more effective cancer treatments. Its efforts contribute to the diversification of therapeutic options available to clinicians, offering hope to patients managing the challenges of cancer. Through strategic partnerships and robust research initiatives, Arcus Biosciences continues to expand its impact within the highly competitive biopharmaceutical sector, underscoring the importance of innovation in the battle against cancer.

CEODr. Terry J. Rosen Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees627

Company Statistics

FY 2025

Profile

$2.84BMarket Cap
$247.00MRevenue
0.00Shares Out
627Employees

Margins

N/AGross
-135.63%EBITDA
-156.28%Operating
-142.91%Pre-Tax
-142.91%Net

Valuation

-8.05P/E
4.50P/B
11.50EV/Sales
-8.15EV/EBITDA
-5.87P/FCF

Growth (CAGR)

30.16%Rev 3Yr
25.93%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-30.84%ROA
-63.26%ROE
-30.14%ROIC

Financial Health

$222.00MCash & Cash Equivalents
$286.00MNet Debt
80.51%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Arcus Biosciences Inc. (ticker: RCUS) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 627 employees. Market cap is $2.8B.

The current price is $26.45 with a P/E ratio of -8.05x and P/B of 4.5x.

ROE is -63.26% and operating margin is -156.28%. Annual revenue is $247M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Arcus Biosciences Inc. (RCUS) Stock Forecast 2026 $26.45 — Price, Financials & Analyst Targets | Alpha Lenz